Goldman Sachs stock rises as Fed week begins and leadership moves hit the tape
26 January 2026
1 min read

Goldman Sachs stock rises as Fed week begins and leadership moves hit the tape

New York, Jan 26, 2026, 10:59 EST — Regular session

  • Goldman Sachs shares nudged up in early trading, tracking gains seen across major U.S. banks.
  • Traders are digesting a shake-up in Goldman’s leadership while navigating a packed macroeconomic calendar this week.
  • The Federal Reserve’s rate decision on Wednesday stands as the next major test for risk appetite.

Goldman Sachs shares climbed roughly 0.9% to $927.04 on Monday, following a trading range of $912.00 to $933.47 earlier in the day.

This matters because bank stocks are caught between two ongoing narratives: the pace of Fed easing and the extent of Washington’s regulatory push. Goldman’s earnings depend largely on trading and deal fees, which fluctuate with changes in rates and risk appetite.

Goldman is also shaking up senior roles, betting more on stable fee businesses to balance its markets franchise.

Wall Street’s major indexes climbed as investors prepared for a busy slate of earnings from the “Magnificent 7” giants and the Federal Reserve’s policy meeting. Adding to the pressure, a U.S. government funding deadline looms on Jan. 30. 1

Goldman Sachs elevated seven partners to its management committee, the firm’s highest decision-making body, in a move that also reshuffles its wealth management leadership, according to a memo obtained by Bloomberg News. The updates bring private credit co-heads James Reynolds and Vivek Bantwal onto the committee, while John Mallory and Nishi Somaiya were named global co-heads of the wealth management division. 2

Goldman moved in step with its peers. JPMorgan Chase climbed around 0.8%, Morgan Stanley gained close to 1.3%, and Bank of America advanced about 0.8%.

The policy environment remains unsettled. President Donald Trump’s $5 billion lawsuit targeting JPMorgan and CEO Jamie Dimon has heightened scrutiny on how fast Washington’s stance can shift, even as banks lobby for looser regulations. “The industry is losing as many battles as it wins on big issues,” said Todd Baker, a senior fellow at Columbia University. 3

The Fed takes center stage this week, with officials likely to hold rates steady. But the meeting comes under renewed political scrutiny, raising doubts about the central bank’s independence. “Trump will need greater turnover at the Fed to fully control the institution,” said Tim Duy, chief U.S. economist at SGH Macro Advisors. 4

That said, the setup is double-edged. Should yields spike or uncertainty around policy intensify—whether from the Fed battle, a shutdown threat, or fresh pressure on risk assets—banks linked to markets and deal flow could lose gains just as fast.

On deck: the Fed holds its two-day meeting from Jan. 27 to 28. The rate decision and press briefing are set for Wednesday, Jan. 28. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Critical Metals stock flips lower after early surge as U.S. rare-earth deal jolts sector
Previous Story

Critical Metals stock flips lower after early surge as U.S. rare-earth deal jolts sector

CleanSpark stock tumbles as bitcoin slips again, putting Feb. 5 earnings in focus
Next Story

CleanSpark stock tumbles as bitcoin slips again, putting Feb. 5 earnings in focus

Go toTop